Trial Profile

A Proof of Concept Study of Imetelstat in Patients with Additional Hematologic Myeloid Malignancies

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imetelstat (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
Focus Therapeutic Use
Sponsors Geron Corporation

Most Recent Events

21 May 2020 According to an Geron Corporation media release, this study originally expected to begin in the fourth quarter of 2020, has been postponed in order to prioritize the Phase 3 clinical trials in lower risk MDS and refractory MF.
02 Apr 2020 According to a Geron Corporation media release, due to covid-19 pandemic we no longer expect to commence our proof of concept study in high risk MDS and AML by the end of 2020, as we had originally planned.
19 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com